Faye Johnson MD PhD, 2026 ENA Targets: Antibody-Drug Conjugate MICVO Targets Extracellular Matrix to Treat Metastatic Head & Neck Cancers After Platinum or Immunotherapy

Home of the Audio Journal of Oncology
Interviews with the world's key opinion leaders in cancer
Latest Episodes
Catch up on the latest insights in oncology.

Faye Johnson MD PhD, 2026 ENA Targets: Antibody-Drug Conjugate MICVO Targets Extracellular Matrix to Treat Metastatic Head & Neck Cancers After Platinum or Immunotherapy
BARCELONA, Spain—Patients with metastatic head and neck cancers that recurred despite platinum based chemotherapy or immunotherapy had significant responses to treatment with the antibody-drug…

Li Zhang MD; ESMO 2026: Bi-Specific Antibody-Drug Conjugate Doubles Progression Free Survival in Patients with NSCLC Progressing After Anti-EGFR TKI Therapy
MADRID, Spain—Patients with EGFR-mutated advanced non-squamous non-small cell lung cancer progressing on third-generation EGFR tyrosine kinase inhibitors lived twice as long without progression when…

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after…

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer…

Kai-Keen Shiu PhD FRCP; CSCO 2026: Immune-Resistant Colorectal Cancer: Making Microsatellite Stable Tumors Immunogenic, Circulating Tumor DNA, Neoadjuvant Immunotherapy
JINAN, China—Biomarker targeting, neoadjuvant immunotherapy and liquid biopsies are among a range of factors promising to make immune-resistant colorectal cancers (such as those with microsatellite…

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer
MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among…

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies
MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III…

Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma
MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the…

James L Reading PhD; Nature 2026: Regulatory T-Cell Axis Identifies Pre-Malignant Lung Cancer
LONDON, United Kingdom—Researchers in London have identified patterns of regulatory T-cells that give early warning of high risk for lung cancer. The journal Nature has just published research…

Joseph Mikhael MD; IMS 2026: Bringing BCMA Therapies to All Patients with Multiple Myeloma at First Relapse
GLASGOW, Scotland—Joseph Mikhael MD, Professor at the Translational Genomics Research Institute (TGen), Phoenix, Arizona USA, talks with Sarah Maxwell at the International Myeloma Society 2026 Annual…

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in…

Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy
GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This…
Stay updated with the latest episodes
Join our newsletter to receive notifications when new oncology updates are published.